PETNet to distribute, co-market MEDRAD PET infusion system

TriMed Staff | | Health Imaging | Diagnostic Imaging
MEDRAD has signed a distribution and co-marketing partnership agreement with PETNet Solutions, a fully owned subsidiary of Siemens Medical Solutions USA.

The agreement will allow healthcare providers to inject fluorodeoxyglucose (FDG) for PET/CT imaging procedures in a new way, according to Warrendale, Pa.-based MEDRAD.

The partnership will leverage MEDRAD’s soon-to-be introduced PET infusion system and multi-dose FDG packaging and delivery from PETNet, the company said.

The company said its PET infusion system, to be called Intego, is designed to automatically extract a patient dose from a multi-dose vial and deliver it directly to the patient. The system is mobile and includes dosimetry, shielding and a touchscreen interface.

TriMed Staff

Related Content

First human X-rays in space to take place during upcoming SpaceX mission
Mycoplasma pneumonia: Experts highlight imaging findings linked to the pediatric diagnosis
AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.